Moderna (MRNA) Expected to Announce Earnings on Thursday

Moderna (NASDAQ:MRNA) is projected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.93) per share and revenue of $977.11 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Moderna Stock Performance

Moderna stock opened at $33.90 on Tuesday. The firm has a market cap of $13.05 billion, a PE ratio of -3.65 and a beta of 1.59. The firm’s 50 day moving average price is $37.89 and its two-hundred day moving average price is $52.10. Moderna has a twelve month low of $29.25 and a twelve month high of $170.47.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on MRNA shares. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Berenberg Bank upped their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. UBS Group decreased their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.